DDInter1840 DDInter193
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022.
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Saxagliptin
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Trabectedin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Trabectedin {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Quinine
Quinine {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Trabectedin {u} (Compound) causes {v} (Side Effect) Left ventricular dysfunction
Left ventricular dysfunction {u} (Side Effect) is caused by {v} (Compound) Ixabepilone
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Saxagliptin (Compound) and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Trabectedin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Berotralstat
Trabectedin (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Quinine (Compound) and Quinine may lead to a major life threatening interaction when taken with Berotralstat
Trabectedin (Compound) causes Left ventricular dysfunction (Side Effect) and Left ventricular dysfunction (Side Effect) is caused by Ixabepilone (Compound) and Ixabepilone may lead to a major life threatening interaction when taken with Berotralstat